Dr. Funda Meric-Bernstam

Dr. Funda Meric-Bernstam, MD is the Chair of the Department of Investigational Cancer Therapeutics (the Phase I Program) at MD Anderson Cancer Center; Medical Director of the Institute for Personalized Cancer Therapy (IPCT) and Professor, Division of Cancer Medicine and Division of Surgery at The University of Texas MD Anderson Cancer Center, Houston, Texas. She is a world-renowned expert in precision oncology, early-phase clinical trials and targeted cancer therapies. * **Professional Credentials** * 25+ years in practice * The University of Texas MD Anderson Cancer Center, Houston, Texas * Precision oncology, investigational cancer therapies, breast surgical oncology, Phase I clinical trials, antibody-drug conjugates (ADCs) * Yale School of Medicine * Fellowship in 1998 at MD Anderson Cancer Center * Board Certified in General Surgery * **Major Contributions** * Inducted as a Fellow to the National Academy of Medicine for her accomplishments in precision oncology, therapeutics and biomarker development, and clinical trial leadership; particularly in conducting game-changing clinical trials that lead to changed clinical practice guidelines of the National Comprehensive Cancer Network and multiple FDA approvals, including the first tumor-agnostic FDA approval of an ADC. * Author of over 600 peer-reviewed manuscripts, has received over $23 million in research grants since starting at MD Anderson and her publications have been cited over 61,000 times with over 1,050 articles written. She is a world-leading expert in early phase cancer drug development and precision oncology. MD Anderson Cancer Center patients can benefit from the most advanced experimental treatments and biomarker-driven treatment approaches available on earth.